239 related articles for article (PubMed ID: 33493719)
1. Association of environmental cadmium exposure and bone remodeling in women over 50 years of age.
Lv YJ; Song J; Xiong LL; Huang R; Zhu P; Wang P; Liang XX; Tan JB; Wang J; Wu SX; Wei QZ; Yang XF
Ecotoxicol Environ Saf; 2021 Mar; 211():111897. PubMed ID: 33493719
[TBL] [Abstract][Full Text] [Related]
2. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
3. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
4. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
Brzóska MM; Moniuszko-Jakoniuk J
Bone; 2004 Nov; 35(5):1180-91. PubMed ID: 15542044
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin and receptor activator of the nuclear factor kappa B ligand (RANKL) in healthy pubertal girls - relationships with physical growth and classical bone turnover markers.
Kulik-Rechberger B; Kozłowska M
J Physiol Pharmacol; 2024 Feb; 75(1):. PubMed ID: 38583439
[TBL] [Abstract][Full Text] [Related]
6. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
[TBL] [Abstract][Full Text] [Related]
7. Smoking and other determinants of bone turnover.
Jorde R; Stunes AK; Kubiak J; Grimnes G; Thorsby PM; Syversen U
PLoS One; 2019; 14(11):e0225539. PubMed ID: 31765401
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of zinc supplementation against cadmium-induced oxidative stress and the RANK/RANKL/OPG system imbalance in the bone tissue of rats.
Brzóska MM; Rogalska J
Toxicol Appl Pharmacol; 2013 Oct; 272(1):208-20. PubMed ID: 23726800
[TBL] [Abstract][Full Text] [Related]
9. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
[TBL] [Abstract][Full Text] [Related]
11. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
[TBL] [Abstract][Full Text] [Related]
12. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
13. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
14. Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.
Seguro LP; Casella CB; Caparbo VF; Oliveira RM; Bonfa A; Bonfa E; Pereira RM
Osteoporos Int; 2015 Feb; 26(2):459-67. PubMed ID: 25146092
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
16. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
[TBL] [Abstract][Full Text] [Related]
17. TGF-β1, bone metabolism, osteoprotegerin, and soluble receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Strzelczyk J; Gołąbek K; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2016; 67(5):493-500. PubMed ID: 27828689
[TBL] [Abstract][Full Text] [Related]
18. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
19. Reference intervals for serum concentrations of three bone turnover markers for men and women.
Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
[TBL] [Abstract][Full Text] [Related]
20. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
